Benefits of 2D-LC/MS/MS in Pharmaceutical Bioanalytics

June 25, 2019

This application demonstrates the 2D-LC/MS/MS analysis of cell supernatants from an in vitro cell suspension-based assay. Superior separation by 2D-LC allowed the analysis of 16 target metabolites within 35 minutes.

Spotlight

Cannamedical® Pharma GmbH

Cannamedical® Pharma GmbH has a pharmaceutical wholesale licence in accordance with 52a of the Medicines Act (AMG) and a permit to handle narcotics in accordance with § 3 of the Act on Narcotics (BtMG). As the only independent German cannabis wholesaler we cooperate with several selected international producers. Our independence guarantees a qualitatively and quantitatively unique range of medical cannabis on the German market. In addition to our independence we were also one of the first companies that received the license to import cannabis to Europe. As the laws in Germany only changed in March 2017, making medical cannabis legal, we were one of the very first to deal with the authorities and have since obtained 7 different licenses, allowing us to import from any GMP production in the world. Thus we are one of the pioneers in the European cannabis industry and have become specialists in GMP processing and authority auditing. With our strong team, we are committed to act responsibly

OTHER WHITEPAPERS
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Paving the way for pharma R&D to use FAIR data

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

Read More
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

How Cellular is Enabling the Digital Supply Chain

whitePaper | January 12, 2020

Supply chains grow more and more complex every day. In response, manufacturers and shippers have been eagerly exploring digital tools that provide actionable insight into the location and condition of in-transit goods. Although there are many technology options when it comes to building a digital supply chain, one type of solution stands out as the most reliable and cost-effective: cellular.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

Application Notes & Whitepapers 2019

whitePaper | December 19, 2019

Welcome to European Pharmaceutical Review’s Application Notes & Whitepapers Supplement 2019. This year’s topics range from analytical techniques for bioprocess investigation, host cell protein analysis and Raman imaging to advice on outsourcing services for product characterisation.

Read More

Spotlight

Cannamedical® Pharma GmbH

Cannamedical® Pharma GmbH has a pharmaceutical wholesale licence in accordance with 52a of the Medicines Act (AMG) and a permit to handle narcotics in accordance with § 3 of the Act on Narcotics (BtMG). As the only independent German cannabis wholesaler we cooperate with several selected international producers. Our independence guarantees a qualitatively and quantitatively unique range of medical cannabis on the German market. In addition to our independence we were also one of the first companies that received the license to import cannabis to Europe. As the laws in Germany only changed in March 2017, making medical cannabis legal, we were one of the very first to deal with the authorities and have since obtained 7 different licenses, allowing us to import from any GMP production in the world. Thus we are one of the pioneers in the European cannabis industry and have become specialists in GMP processing and authority auditing. With our strong team, we are committed to act responsibly

Events